CLINICAL TRIALS PROFILE FOR LENVATINIB MESYLATE
✉ Email this page to a colleague
All Clinical Trials for LENVATINIB MESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02430714 ↗ | Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T) | Completed | Eisai Co., Ltd. | 2015-05-20 | This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder. | |
| NCT02579616 ↗ | Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy | Completed | Eisai Co., Ltd. | Phase 2 | 2015-10-23 | This is a multicenter, single arm, open-label study in participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent). This study contains 3 phases: a Pre-treatment phase that will last within 21 days; a Treatment phase that will consist of study treatment cycles and tumor assessment conducted every 6-8 weeks; and a Follow-up phase that will begin immediately after the Off-Treatment Visit and will continue as long as the participant is alive, unless the participant withdraws consent, or until the End of Study. |
| NCT02592356 ↗ | Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | Active, not recruiting | National Cancer Institute (NCI) | N/A | 2015-11-16 | The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib. |
| NCT02592356 ↗ | Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer | Active, not recruiting | M.D. Anderson Cancer Center | N/A | 2015-11-16 | The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LENVATINIB MESYLATE
Condition Name
| Condition Name for LENVATINIB MESYLATE | |
| Intervention | Trials |
| Stage IVB Differentiated Thyroid Gland Carcinoma | 1 |
| Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | 1 |
| Radiotherapy; Complications | 1 |
| Stage IIB Pancreatic Cancer AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for LENVATINIB MESYLATE
Trials by Country
Clinical Trial Progress for LENVATINIB MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for LENVATINIB MESYLATE
Sponsor Name
